I'm LongbridgeAI, I can summarize articles.RXRX.US rallied 19.69% this week to close at $3.83, compared with a 0.08% dip for the S&P 500, outperforming the benchmark by roughly 19.77 percentage points. The move was front-loaded: Monday opened at $3.19 and pushed higher, Wednesday briefly pulled back to $3.16, then Thursday and Friday saw volume expand sharply. Friday closed at the week’s high of $3.83 on 44.3m shares, the heaviest daily turnover of the five sessions. The weekly range was 21%, well above its recent norm.
The Week
RXRX.US rallied 19.69% this week to close at $3.83, compared with a 0.08% dip for the S&P 500, outperforming the benchmark by roughly 19.77 percentage points. The move was front-loaded: Monday opened at $3.19 and pushed higher, Wednesday briefly pulled back to $3.16, then Thursday and Friday saw volume expand sharply. Friday closed at the week’s high of $3.83 on 44.3m shares, the heaviest daily turnover of the five sessions. The weekly range was 21%, well above its recent norm.
Key Events
The week’s story centred on AI-driven drug discovery assets and partnership milestones. On Tuesday 15 September, the company announced that its AI-driven drug discovery platform had delivered first-in-class assets and hit major partnership milestones; the same day saw market commentary grouping RXRX with the broader AI healthcare theme. On Thursday 17 September, Recursion published a full transcript of its Q2 2026 earnings call, adding operational and R&D detail. On Friday 18 September, the stock jumped 10.8% in a single session, sparking debate about whether it was a buying opportunity. No material filings or routine disclosure noise surfaced during the week.
Analyst Ratings
Coverage totals 8 brokers: 1 buy, 2 over, 4 hold and 1 no opinion, with no under or sell ratings. The consensus recommendation is buy, with a consensus target of $7.21667, about 88.42% above the week’s close of $3.83. Targets range from $4.000 to $10.000, pointing to wide disagreement. Within the biotechnology industry the stock ranks 167th out of 501 names, placing it in the middle-to-lower tier.
The Week Ahead
The macro calendar is back-loaded. On Tuesday 22 September the Richmond Fed composite index is due (prior 4). Wednesday 23 September brings EIA weekly crude and Cushing inventories. Thursday 24 September features initial jobless claims (prior 196), the current account balance (prior -226.8), new home sales annualised (forecast 0.608) and natural gas storage changes. On the company side no earnings or major events are scheduled, so attention is likely to stay on AI healthcare sentiment and the broader macro tape.
In Short
RXRX.US gained nearly 20% this week and outpaced the S&P 500 by close to 20 percentage points. The consensus target sits 88.42% above spot, yet the rating mix is skewed toward hold and target dispersion is wide. The latest session’s money flow shows large and medium lots as net buyers while small lots turn net sellers, so the direction is not settled. On valuation, earnings per share are negative and the P/E is not meaningful; the price-to-book ratio is about 2.24x and turnover of 8.64% points to active trading. The question ahead is whether tangible progress on AI-discovered assets can sustain the momentum, and whether macro data shifts risk appetite for growth names.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.